Welcome to our dedicated page for Oruka Therapeutics SEC filings (Ticker: ORKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
Oruka Therapeutics, Inc. reported that Chief Executive Officer and director Lawrence Otto Klein received new equity awards on January 23, 2026. He was granted 306,700 employee stock options with an exercise price of $34.39 per share, covering the right to buy 306,700 shares of common stock, for which he paid $0 at grant. These options vest as to 1/48 of the underlying shares monthly starting January 1, 2026 and expire on January 22, 2036. In addition, he acquired 76,700 shares of common stock at a price of $0, bringing his directly held common stock position to 929,038 shares. That stock grant vests in 1/16 increments on each March 14, June 14, September 14, and December 14, or the prior trading day if needed.
Oruka Therapeutics, Inc. reported that its General Counsel, Paul T. Quinlan, received new equity awards on January 23, 2026.
He acquired 32,500 shares of common stock at a price of $0, held directly. This grant vests as to 1/16 of the shares on each March 14, June 14, September 14 and December 14 (or if not a trading day, the immediately preceding trading day).
Quinlan was also granted an employee stock option for 130,000 shares of common stock at an exercise price of $34.39 per share, expiring on January 22, 2036. The option vests as to 1/48 of the underlying shares monthly from January 1, 2026.
Oruka Therapeutics director Carl Dambkowski reported receiving 116,483 shares of common stock on January 23, 2026. The Form 4 shows the shares were acquired at a price of $0.00 through a transaction coded "J," which the footnote explains as a pro-rata distribution from a limited liability company in which he is a member. After this distribution, he beneficially owns 116,483 shares of Oruka common stock in direct form.
BlackRock, Inc. has reported a passive ownership stake in Oruka Therapeutics, Inc. common stock. BlackRock beneficially owns 3,175,483 shares, representing 6.6% of Oruka’s outstanding common stock as of the event date of 12/31/2025. It has sole power to vote 3,128,050 shares and sole power to dispose of 3,175,483 shares, with no shared voting or dispositive power.
The filing states that the securities were acquired and are held in the ordinary course of business and are not intended to change or influence control of Oruka Therapeutics. Various underlying clients or investors have rights to dividends or sale proceeds, but no single person has more than five percent of the total outstanding common shares.
Oruka Therapeutics, Inc. Chief Medical Officer Joana Goncalves reported option and warrant exercises followed by stock sales. On January 15, 2026, she exercised an employee stock option for 3,500 shares of common stock at $6.84 per share and an employee warrant for another 3,500 shares at $7.8 per share.
That same day, she sold 4,381 shares of common stock at a weighted average price of $31.5626 and 2,619 shares at a weighted average price of $32.237, all under a Rule 10b5-1 trading plan entered into on September 19, 2025. After these transactions, she directly owned 1,518 shares of common stock, as well as 221,563 employee stock options and 192,992 employee warrants.
Oruka Therapeutics, Inc. director Christopher Martin reported receiving stock options to purchase 35,000 shares of the company’s common stock at an exercise price of $30.21 per share on December 11, 2025.
The options expire on December 10, 2035 and vest in equal monthly installments, with 1/36 of the underlying shares vesting each month starting December 11, 2025. After this grant, he beneficially owns options for 35,000 shares, held directly.
Oruka Therapeutics, Inc. director Christopher Martin has filed an initial beneficial ownership report indicating that he does not beneficially own any of the company’s securities. The report, dated 12/11/2025, is filed by a single reporting person and confirms that no non-derivative or derivative securities of Oruka Therapeutics are beneficially owned.
Oruka Therapeutics, Inc. reported that director Cameron Turtle resigned from its Board of Directors on December 11, 2025. The company stated that his resignation was not due to any disagreement over Oruka’s operations, policies, or practices.
On the same day, the board elected Christopher Martin as a Class II director, with a term ending at the 2026 annual meeting of stockholders, and named him Chair of the Compensation Committee and a member of the Audit Committee. As a non-employee director, he received a stock option for 35,000 shares of Oruka common stock vesting in 36 equal monthly installments and is eligible for annual cash retainers of $40,000 for board service, $12,000 for chairing the Compensation Committee, and $7,500 for Audit Committee service. The board determined he is independent under SEC and Nasdaq standards and reported no related-party transactions.
Oruka Therapeutics reported a third‑quarter net loss of $30.277 million as it advanced clinical programs in psoriasis and other I&I indications. Operating expenses were $34.105 million, driven by $28.988 million in R&D and $5.117 million in G&A. Interest income of $3.832 million partially offset expenses. Basic and diluted net loss per common share was $0.55.
Liquidity strengthened: as of September 30, 2025, cash, cash equivalents, and marketable securities totaled $500.9 million. Management expects this balance to fund operating plans for at least twelve months from issuance of the financial statements.
Financing activity included a 2025 PIPE of 10,933,405 common shares at $15.00 and 1,066,666 pre‑funded warrants at $14.999, for net proceeds of approximately $169.6 million. On October 3, 2025, the company established an ATM program permitting sales of up to $200.0 million of common stock. Program spend included milestone expenses, such as $3.0 million for ORKA‑001 upon first dosing in a Phase 2 trial and earlier‑year milestones for ORKA‑002.
Oruka Therapeutics, Inc. (ORKA) filed a prospectus to register up to 39,425,806 shares of common stock for resale by selling stockholders. This is a secondary offering; the company is not selling shares and will not receive proceeds from stockholder sales. The filing states the company will receive only the nominal cash exercise price if holders exercise pre-funded warrants for cash.
The registered shares include 7,083,000 September 2024 Private Placement Common Shares (including shares issued upon Series A Preferred conversion in November 2024), 680,000 shares issuable upon exercise of September 2024 pre-funded warrants, 10,933,405 September 2025 Private Placement Common Shares, 1,066,666 shares issuable upon exercise of September 2025 pre-funded warrants, and 19,662,735 Additional Fairmount Holdings, which include 2,936,922 common shares, 5,297,664 pre-funded warrant shares, and 11,428,149 shares issuable upon conversion of 137,138 shares of Series B Preferred Stock.
Shares outstanding were 48,384,150 as of September 19, 2025. The company’s common stock trades on Nasdaq as “ORKA,” and the last reported sale price was $19.18 per share on October 2, 2025.